The Department of National Defence (DND), specifically the Canadian Forces Health Services
(CFHS), has a requirement for the services of a Contractor to test and evaluate the feasibility of
manufacturing HI-6 DMS and atropine sulfate drug products in a reconstitution autoinjector device
(RAD).
The scope of this requirement is to conduct a feasibility assessment using an existing prototype
of a RAD with the configuration of HI-6 DMS in the dry chamber (500 mg +/- 25%) and 1 mL
atropine (2 mg/mL) in the liquid chamber.
The work will involve the following:
• Project Management.
• Analytical Method Development.
• Material Processing and Performance Assessments.
• Mixing and Drug Delivery Model.
• Sterilization Impact Assessment.